



PRESS RELEASE

June 10th, 2025

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Paris, France, June 10th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain.

The poster will feature new preclinical data on EGL-003, a novel investigational therapy designed to restore immune balance by selectively stimulating Tregs. It will present results from the MuTreg non-interventional trial (NCT05544448), which confirm high Treg selectivity using cells from 78 patients with various autoimmune diseases. In addition, non-clinical studies in non-human primates, along with preclinical efficacy data from a mouse model, will highlight how EGL-003 has the potential to restore immune balance in inflamed tissues.

Based in part on these data, Egle anticipates advancing EGL-003 into a Phase I clinical trial in an autoimmune disease indication in the second half of 2025.

Details of the poster presentation are as follows:

- **Abstract Number:** 581
- **Poster Board Number:** F149
- **Poster Title:** EGL-003: an optimized IL-2 mutein designed to expand regulatory T cells for the treatment of autoimmune diseases
- **Session Title:** Poster View I
- **Session Date and Time:** Wednesday, June 11, 2025, 15:30 - 16:30 CEST
- **Location:** Poster Area, Walkway Hall 6 & 7, Ground Floor

Additional information, including the accepted abstract, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available on the company's website following the event.

About Egle Therapeutics SAS (Egle)

Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.

Egle Therapeutics' lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in the second half of 2025.

Find out more at www.egle-tx.com

Contacts

contact@egle-tx.com / 0033 (0)1 86 64 08 57

investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57